Literature DB >> 7077322

Copper metabolism in rats given di- or trithiomolybdates.

I Bremner, C F Mills, B W Young.   

Abstract

As one of a series of studies on the influence of S substitution of MoO4(2-) on the action of Mo as an antagonist of Cu, the effects of MoO2S2(2-) and MoOS3(2-) on the metabolism of Cu by rats have been investigated. Administration of either oxythiomolybdate increased both plasma Cu concentration and the retention of Cu by the albumin fraction of plasma. In contrast to the effects of MoS4(2-), described previously, neither oxythiomolybdate inhibited 64Cu absorption from the digestive tract or induced biochemical or clinical signs of Cu deficiency. Evidence is discussed suggesting that the potency of the thio- and oxythiomolybdates as inhibitors of Cu utilization is directly proportional to the degree of thio substitution within the series series MoO4- chi S chi 2-.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7077322     DOI: 10.1016/s0162-0134(00)80219-6

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  4 in total

1.  Copper chelation by tetrathiomolybdate inhibits lipopolysaccharide-induced inflammatory responses in vivo.

Authors:  Hao Wei; Balz Frei; Joseph S Beckman; Wei-Jian Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-01       Impact factor: 4.733

Review 2.  Practical recommendations and new therapies for Wilson's disease.

Authors:  G J Brewer
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

3.  Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Andrew K Vine; George J Brewer
Journal:  Trans Am Ophthalmol Soc       Date:  2002

4.  Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.

Authors:  MengMeng Xu; Michael Casio; Danielle E Range; Julie A Sosa; Christopher M Counter
Journal:  Clin Cancer Res       Date:  2018-07-31       Impact factor: 13.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.